Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Regeneron Touts Potential Of Growing Eylea Franchise After Robust Q4

This article was originally published in The Pink Sheet Daily

Executive Summary

Speaking at the J.P. Morgan meeting in January, Regeneron CEO Leonard Schleifer says the company is exploring many opportunities to build the franchise around its successful wet AMD drug Eylea. In the fourth quarter, the drug racked up $400 million in U.S. sales, beating expectations.

Advertisement

Related Content

Regeneron Emphasizes Pipeline Promise As Eylea Pricing Pressure Builds
Deal Watch: Bristol Places Early Wager On Padlock's Autoimmune Potential
Regeneron/Bayer Partnership Seeks To Build Upon Eylea's Success
First Quarter Earnings Dampened By Severe Weather
Ophthotech Underscores Limitations Of Anti-VEGFs in Wet AMD
Hang Onto The Launch: Investor Outlook Is Brighter For Some Biotechs
Regeneron Plays It Safe With Eylea, Aims To Undercut Lucentis
Avastin-Related Eye Infections Could Bring FDA Pressure On Compounding Pharmacies

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS076395

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel